Harbour BioMed converts SPR202 partnership into strategic stake in Spruce Biosciences
Harbour BioMed acquires stake in Spruce Biosciences, reinforcing its SPR202 collaboration. Find out what this signals for CRH-targeted therapies.
Pharma & Biotech
Pharma & Biotech
What AstraZeneca’s C-CAR031 deal reveals about the future of CAR-T in liver cancer
AstraZeneca takes full control of a GPC3 CAR-T therapy for liver cancer. Find out what this deal changes and what risks still loom.
Pharma & Biotech
What D3 Bio’s dual KRAS IND clearances reveal about the next wave of targeted oncology
D3 Bio secures U.S. FDA IND clearances for two KRAS programs, advancing G12D monotherapy and G12C resistance combo trials. See what this means for oncology.
Pharma & Biotech
Organon’s NEXPLANON gains FDA nod for five-year use, but REMS adds new provider hurdles
Organon’s etonogestrel implant NEXPLANON has received FDA approval for extended use up to five years, marking a significant regulatory win for the women’s health–focused pharmaceutical company. The decision, which comes via a supplemental new drug application (sNDA), builds on existing data supporting the implant’s high efficacy and safety profile and broadens its potential utility among
Pharma & Biotech
ImmunityBio’s CAR-NK cell therapy achieves 15-month remission in Waldenström lymphoma
Find out how ImmunityBio’s CD19 CAR-NK cell therapy may change treatment for Waldenström lymphoma with durable responses and no chemotherapy.
Medical Devices & Diagnostics
Will cartridge-based CBC systems replace central labs? Henry Schein bets on it with CitoCBC
Find out how Henry Schein’s exclusive U.S. deal for CytoChip’s CLIA-waived CitoCBC could reshape point-of-care blood diagnostics.
Medical Devices & Diagnostics
What EndoQuest’s PARADIGM Trial approval reveals about robotic ESD innovation in GI surgery
EndoQuest wins FDA approval to complete PARADIGM Trial for its ELS system. Find out what this milestone means for robotic GI surgery innovation.
Medical Devices & Diagnostics
Why Provation’s iPro Lite could signal the end of paper-based anesthesia workflows
Provation launches iPro Lite for mobile anesthesia documentation. Find out how it could change billing, compliance, and risk in outpatient surgery centers.
Pharma & Biotech
Organon’s NEXPLANON earns five-year approval: How this changes the LARC landscape
FDA approves NEXPLANON for five years of use with REMS program. Find out how this reshapes contraceptive access, safety, and policy impact.
Pharma & Biotech
XenoTherapeutics’ takeover of Repare wins near-unanimous vote: What’s at stake for the pipeline
Repare shareholders approve XenoTherapeutics deal. Find out how this nonprofit acquisition could reshape oncology pipeline models.